NTLA Earnings Results and History
Intellia Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.91 vs −$0.80 est −14.2%
- Revenue$7.2M vs $9.7M est −26.5%
- Revenue growth−48.0% vs a year ago
Filed ยท Press release
Key takeaways
from the press release- Collaboration revenue fell to $7.2 million from $13.8 million, mainly due to lower revenue from Regeneron.
- R&D expense dropped to $83.3 million from $94.7 million, driven by lower external lonvo-z costs and lower stock-based compensation.
EPS by quarter
GAAP diluted, 12 quartersRevenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Op margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| Jun 2026 | $7.7M | −46.2% | −1472.3% | −$106.6M | −$0.80 | −$84.9M |
| Mar 2026 | $15M | −9.5% | −668.1% | −$96.2M | −$0.81 | −$117.4M |
| Dec 2025 | $23M | +78.8% | −428.9% | −$95.8M | −$0.82 | −$69.4M |
| Sep 2025 | $13.8M | +51.3% | −808.9% | −$101.3M | −$0.92 | −$76.9M |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Year by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $67.7M | +16.9% | −651.7% | −$412.7M | −$3.81 |
| Dec 31, 2024 | $57.9M | +59.6% | −923.1% | −$519M | −$5.25 |
| Dec 31, 2023 | $36.3M | −30.4% | −1420.5% | −$481.2M | −$5.42 |
| Dec 31, 2022 | $52.1M | +57.7% | −879.0% | −$474.2M | −$6.16 |
| Dec 31, 2021 | $33.1M | – | −810.4% | −$267.9M | −$3.78 |
Filings and dates
SEC EDGAR- Nov 5, 2026Earnings release, Q3 20268-K Press release
- Nov 5, 2026Next earnings reportexpected
- Aug 6, 2026Quarterly report10-Q All filings
Also see NTLA institutional ownership and the earnings calendar.
NTLA earnings FAQ
What were NTLA's latest earnings?
For Q3 2026 Intellia Therapeutics, Inc. reported revenue of $7.2M, GAAP EPS of -$0.91. The results were filed with the SEC on Nov 5, 2026.
When is NTLA's next earnings date?
Intellia Therapeutics, Inc. is expected to report on Nov 5, 2026. Dates can move until the company confirms them.
Is NTLA's revenue growing?
In the quarter ended Jun 30, 2026 revenue was $7.7M, down 46.2% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from Intellia Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.